Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
6(55%)
Results Posted
67%(2 trials)
Terminated
2(18%)

Phase Distribution

Ph early_phase_1
3
27%
Ph phase_2
4
36%
Ph not_applicable
1
9%
Ph phase_1
2
18%
Ph phase_3
1
9%

Phase Distribution

5

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
3(27.3%)
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
1(9.1%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

6

trials recruiting

Total Trials

11

all time

Status Distribution
Active(6)
Completed(3)
Terminated(2)

Detailed Status

Active, not recruiting3
Recruiting3
Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
6
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 13 (27.3%)
Phase 12 (18.2%)
Phase 24 (36.4%)
Phase 31 (9.1%)
N/A1 (9.1%)

Trials by Status

active_not_recruiting327%
recruiting327%
completed327%
terminated218%

Recent Activity

6 active trials
Showing 5 of 11
recruitingphase_1

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

NCT03965234
completedphase_2

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

NCT03796767
active_not_recruitingphase_2

Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

NCT03599752
active_not_recruitingearly_phase_1

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

NCT02210117
active_not_recruitingearly_phase_1

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

NCT06011772
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03965234Phase 1

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Recruiting
NCT03796767Phase 2

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

Completed
NCT03599752Phase 2

Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

Active Not Recruiting
NCT02210117Early Phase 1

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Active Not Recruiting
NCT06011772Early Phase 1

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Active Not Recruiting
NCT02738606Phase 2

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

Terminated
NCT03473730Early Phase 1

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

Completed
NCT06585007Phase 3

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

Recruiting
NCT06121700Phase 2

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Recruiting
NCT01106261Not Applicable

A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer

Completed
NCT02595918Phase 1

Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery

Terminated

All 11 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
11